Cunningham Everett
Known title: DirectorCIK: 0001564777
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Transaction History
| ARVN | ▲ Buy | Grant | 15,527 | $0 | 6/24/2026 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 4,248 | $413K | 7/5/2025 | View on chart |
| ARVN | ▲ Buy | Grant | 16,025 | $0 | 6/25/2025 | View on chart |
| ILMN | ▲ Buy | Grant | 9,103 | $0 | 3/5/2025 | View on chart |
| ILMN | ▲ Buy | Grant | 36,860 | $0 | 7/5/2024 | View on chart |
| ARVN | ▲ Buy | Grant | 5,899 | $0 | 5/29/2024 | View on chart |
| ARVN | ▲ Buy | Grant | 4,121 | $0 | 6/15/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Arvinas Releases Q2 2026 Earnings Call Transcript
Arvinas has published the transcript of its Q2 2026 earnings call. The document contains the company's financial results, guidance, and management commentary. Investors can use the transcript to assess the company's recent performance and future outlook.
Arvinas Releases Q2 2026 Earnings Call Transcript. Arvinas has published the transcript of its Q2 2026 earnings call. The document contains the company's financial results, guidance, and management commentary. Investors can use the transcript to assess the company's recent performance and future outlook.